The Singapore firm is a unit of European healthcare firm Fresenius SE .
The Indian firm, which makes anti-cancer drugs, had earlier this year denied it was in talks with a German drug maker for a partnership or sale. The deal with Fresenius values it about 10 percent higher from its market capitalisation of $273 million.
Last year, the company had sold its non-oncology drugs business to local rival Alembic to focus on cancer treatment drugs.(Reuters)